{"id":73,"date":"2026-03-10T17:58:49","date_gmt":"2026-03-10T16:58:49","guid":{"rendered":"https:\/\/epilogy.org\/?p=73"},"modified":"2026-03-24T14:04:57","modified_gmt":"2026-03-24T13:04:57","slug":"expertise","status":"publish","type":"post","link":"https:\/\/epilogy.org\/fr\/expertise","title":{"rendered":"Expertise"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"73\" class=\"elementor elementor-73\">\n\t\t\t\t<div class=\"elementor-element elementor-element-09670b3 e-flex e-con-boxed e-con e-parent\" data-id=\"09670b3\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-79e095c elementor-widget elementor-widget-heading\" data-id=\"79e095c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Une expertise mondiale en recherche dermatologique et recommandations<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0a0e654 elementor-widget elementor-widget-html\" data-id=\"0a0e654\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t<style>\n\n.epilogy-review{\n  background:#fff;\n  border:1px solid #ead3ee;\n  border-left:5px solid #7C2A86;\n  border-radius:8px;\n  padding:20px;\n  margin:24px 0;\n}\n\n.epilogy-review h3{\n  font-size:14px;\n  color:#7C2A86;\n  margin:18px 0 10px 0;\n  line-height:1.4;\n  padding-top:12px;\n  border-top:1px solid #f3e6f6;\n}\n\n.epilogy-review p{\n  font-size:13px;\n  color:#54595F;\n  line-height:1.7;\n  margin:0 0 12px 0;\n}\n\n.epilogy-review ul{\n  margin:0 0 14px 18px;\n  padding:0;\n}\n\n.epilogy-review li{\n  font-size:13px;\n  color:#54595F;\n  line-height:1.7;\n  margin:0 0 8px 0;\n}\n\n.epilogy-review strong{\n  color:#7C2A86;\n  font-weight:600;\n}\n\n@media (max-width:767px){\n  .epilogy-review{\n    padding:16px;\n  }\n}\n\n<\/style>\n\n<div class=\"epilogy-review\">\n\n<h3>Centres de r\u00e9f\u00e9rence internationaux et r\u00e9seaux de recherche<\/h3>\n\n<p>Les membres de l\u2019\u00e9quipe sont fortement impliqu\u00e9s dans des centres nationaux de r\u00e9f\u00e9rence pour les maladies rares, notamment :<\/p>\n\n<ul>\n<li>Centre de r\u00e9f\u00e9rence des dermatoses bulleuses et toxidermies graves <strong><a href=\"https:\/\/toxibul.fr\/\" target=\"_blank\">TOXIBUL<\/a><\/strong> (Saskia Oro, directrice).<\/li>\n<li>Centre de r\u00e9f\u00e9rence des maladies bulleuses auto-immunes <strong><a href=\"https:\/\/fimarad.org\/centres-malibul\/#creteil\" target=\"_blank\">MALIBUL<\/a><\/strong> (Saskia Oro, directrice).<\/li>\n<li>Centre de r\u00e9f\u00e9rence des neurofibromatoses France <strong><a href=\"https:\/\/cerenef.org\/en\/\" target=\"_blank\">CERENEF<\/a><\/strong> (Thomas Bettuzzi, comit\u00e9 scientifique).<\/li>\n<\/ul>\n\n<p>Les membres sont \u00e9galement impliqu\u00e9s dans des r\u00e9seaux internationaux majeurs :<\/p>\n\n<ul>\n<li><strong><a href=\"https:\/\/ern-skin.eu\/\" target=\"_blank\">R\u00e9seau europ\u00e9en de r\u00e9f\u00e9rence pour les maladies rares de la peau (ERN-Skin)<\/a><\/strong> \u2014 Saskia Oro, responsable du groupe sur les dermatoses bulleuses toxiques et les r\u00e9actions s\u00e9v\u00e8res aux m\u00e9dicaments (<a href=\"https:\/\/ern-skin.eu\/toxiten\/\" target=\"_blank\">ToxiTEN<\/a>).<\/li>\n<li><strong><a href=\"https:\/\/eadv.org\/\" target=\"_blank\">European Academy of Dermatology and Venereology (EADV)<\/a><\/strong> \u2013 Task force \u00e9pid\u00e9miologie \u2014 \u00c9milie Sbidian, co-responsable.<\/li>\n<li><strong><a href=\"https:\/\/www.globalvitiligoatlas.org\/\" target=\"_blank\">Global Atlas on Vitiligo<\/a><\/strong> \u2013 <a href=\"https:\/\/www.ilds.org\/\" target=\"_blank\">International League of Dermatological Societies (ILDS)<\/a> \u2014 Khaled Ezzedine (responsable et comit\u00e9 de pilotage).<\/li>\n<li><strong><a href=\"https:\/\/esdr.org\/\" target=\"_blank\">European Society of Epidemiology in Dermatology (ESDR)<\/a><\/strong> \u2014 \u00c9milie Sbidian (comit\u00e9 de pilotage), Khaled Ezzedine et Laurence Le Cleach (comit\u00e9 scientifique).<\/li>\n<li><strong><a href=\"https:\/\/skin.cochrane.org\/fr\" target=\"_blank\">Groupe Cochrane Skin<\/a><\/strong> \u2014 Laurence Le Cleach (directrice), \u00c9milie Sbidian (membre).<\/li>\n<li><strong>CHORD Cochrane Collaboration<\/strong> \u2014 Khaled Ezzedine (co-pr\u00e9sident du groupe m\u00e9thodes et comit\u00e9 de pilotage).<\/li>\n<\/ul>\n\n<h3>Pharmaco-\u00e9pid\u00e9miologie et translation clinique<\/h3>\n\n<p>Notre forte orientation en pharmaco-\u00e9pid\u00e9miologie nous conduit \u00e0 rapprocher au maximum nos r\u00e9sultats de leur utilisation clinique. Notre expertise en revues syst\u00e9matiques et m\u00e9ta-analyses nous permet de synth\u00e9tiser les donn\u00e9es sur l\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 des traitements disponibles pour une maladie inflammatoire \u00e0 m\u00e9diation immunitaire (IMID).<\/p>\n\n<p>Ces travaux ont conduit au d\u00e9veloppement de collaborations avec des groupes internationaux d\u2019\u00e9laboration de recommandations au niveau :<\/p>\n\n<ul>\n<li>National \u2014 <a href=\"https:\/\/www.bad.org.uk\/\" target=\"_blank\">British Academy of Dermatologists (BAD)<\/a>.<\/li>\n<li class=\"translation-block\">Europ\u00e9en \u2014 <a href=\"https:\/\/www.guidelines.edf.one\/\" target=\"_blank\">EuroGuiDerm<\/a>.<\/li>\n<li>Canadien \u2014 <a href=\"https:\/\/www.cda-amc.ca\/\" target=\"_blank\">Canadian Agency for Drugs and Technologies in Health (CADTH)<\/a>.<\/li>\n<li class=\"translation-block\">Am\u00e9ricain \u2014 <a href=\"https:\/\/www.aad.org\/\" target=\"_blank\">American Academy of Dermatology (AAD)<\/a>.<\/li>\n<\/ul>\n\n<h3>Donn\u00e9es en vie r\u00e9elle et bases de donn\u00e9es nationales de sant\u00e9<\/h3>\n\n<p>Nous avons d\u00e9velopp\u00e9 une expertise solide dans l\u2019utilisation de la base m\u00e9dico-administrative fran\u00e7aise, permettant l\u2019acc\u00e8s \u00e0 de larges populations n\u00e9cessaires pour \u00e9valuer le profil r\u00e9el de s\u00e9curit\u00e9 des m\u00e9dicaments.<\/p>\n\n<p>Cette expertise nous a conduits \u00e0 collaborer avec des acteurs des politiques de sant\u00e9 et \u00e0 intervenir en tant qu\u2019experts aupr\u00e8s d\u2019agences sanitaires nationales et europ\u00e9ennes, notamment <a href=\"https:\/\/www.ema.europa.eu\/en\/homepage\" target=\"_blank\">The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency's (EMA) committee <\/a> et <a href=\"https:\/\/www.has-sante.fr\/\" target=\"_blank\">la Haute Autorit\u00e9 de Sant\u00e9 (HAS)<\/a>.<\/p>\n\n<h3>Outils d\u2019aide \u00e0 la d\u00e9cision clinique<\/h3>\n\n<p>Notre activit\u00e9 d\u00e9di\u00e9e aux effets ind\u00e9sirables cutan\u00e9s des m\u00e9dicaments et \u00e0 l\u2019imputabilit\u00e9 a conduit \u00e0 la cr\u00e9ation d\u2019un outil d\u2019aide \u00e0 la d\u00e9cision (<strong>D\u00e9citox<\/strong>), con\u00e7u pour accompagner les cliniciens non dermatologues dans leur pratique quotidienne.<\/p>\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Global Expertise in Dermatology Research and Guidelines International referral centers and research networks Team members are strongly involved in national referral centers of rare diseases, including: National referral center for toxic bullous diseases and severe skin adverse reactions TOXIBUL (Saskia Oro, leader). Competence center for auto-immune bullous dermatoses MALIBUL (Saskia Oro, leader). National referral center&hellip;&nbsp;<a href=\"https:\/\/epilogy.org\/fr\/expertise\" rel=\"bookmark\"><span class=\"screen-reader-text\">Expertise<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":628,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":70,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","neve_meta_reading_time":"","footnotes":""},"categories":[1,9],"tags":[],"class_list":["post-73","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-epilogy","category-expertise-data-sources"],"_links":{"self":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts\/73","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/comments?post=73"}],"version-history":[{"count":11,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts\/73\/revisions"}],"predecessor-version":[{"id":629,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts\/73\/revisions\/629"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/media\/628"}],"wp:attachment":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/media?parent=73"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/categories?post=73"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/tags?post=73"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}